Company

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World's First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer
ADC / XDCAlphamab Oncology

Alphamab Oncology Doses First Patient in Phase III Trial of JSKN033 – World’s First High‑Concentration Subcutaneous HER2 ADC/PD‑L1 Fixed‑Dose Combination for Recurrent Cervical Cancer

Alphamab Oncology (HKG: 9966) announced that the first patient has been successfully dosed in the Phase III clinical study of JSKN033 monotherapy for recurrent or metastatic cervical cancer – irrespective…

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Junshi Biosciences Converts Loqtorzi Urothelial Carcinoma Indication to Full Approval; Subcutaneous Toripalimab (JS001sc) NDA Accepted in First‑Line HER2‑Expressing Disease

Eli Lilly's Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Eli Lilly’s Retatrutide Beats Ozempic Head‑to‑Head in Phase 3 TRANSCEND-T2D-2 – Greater A1C Reduction and Roughly Double the Weight Loss in Type 2 Diabetes

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
BiosimilarsFosun Pharmaceutical

Fosun Secures FDA Approval for Two Denosumab Biosimilar Formulations

Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977
Clinical trial approval / initiationHaisco Pharmaceutical

Haisco Secures FDA Clinical Trial Approval for First‑In‑Class BCL6 PROTAC HSK47977

Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China
Market launchOphthalmology

Santen Launches Tapcom, Preservative‑Free Glaucoma Combo in China

ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies
ChemPartner PharmatechCRO / CMO / CDMO

ChemPartner & Hayoo Forge Nucleic‑Acid Delivery Partnership to Expand Extranodal Therapies

Show More